newsfilter
← Latest News
GlobeNewswire·

Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 NDA submission for sofpironium bromide gel, 15% anticipated in mid-2022 pending Phase 3 outcome BOULDER, Colo., Aug. 16, 2021 (GLOBE NEWSWIR